Latest Conference Articles

Dr Caimi on Early Data for LMY-920 in R/R B-Cell NHL

Paolo Caimi, MD, discusses the rationale behind evaluating LMY-920, a novel BAFF CAR T-cell therapy, in relapsed/refractory non-Hodgkin lymphoma.

Navigating a “Sea Change” in Frontline Urothelial Carcinoma Treatment

David H. Aggen, MD, PhD, details the evolving landscape of treating patients with urothelial carcinoma.

Dr Scalici on Data for IMNN-001 Plus SOC Chemotherapy in Advanced Ovarian Cancer

Jennifer Scalici, MD, discusses data for IMNN-001plus chemotherapy in advanced ovarian cancer.

Dr Lin on the Safety of NKTR-255 in Enhancing Immune Recovery Post-Chemoradiation in Locally Advanced NSCLC

Steven H. Lin, MD, PhD, discusses the safety of NKTR-255 in enhancing immune recovery post-chemoradiation in locally advanced NSCLC.

Dr Weiss on the Role of Breast Imaging in Breast Cancer Treatment Decision-Making

Anna Weiss, MD, discusses the significance of various imaging modalities in patients with breast cancer.

Dr Herbst on the Evolution of EGFR Inhibition in Lung Cancer

Roy S. Herbst, MD, PhD, discusses advances in EGFR inhibition throughout the past several decades in patients with lung cancer.

2024 Updates in GI Cancer Feature FLOT Combinations, Restricted FDA Approvals by PD-L1 Expression, and More

Yelena Y. Janjigian, MD, highlights key takeaways and data from 2024 in the gastric and GEJ cancer field.

Transposon-Based BAFF CAR T Cells Show Early Efficacy, Safety in R/R Non-Hodgkin Lymphoma

Piecing Together the Proper BTK Usage in CLL

Nicole Lamanna, MD, highlights various clinical trials underway evaluating new treatment options for patients with chronic lymphocytic leukemia.

Real-World Experience With CAR T Varies From Trials in DLBCL

When evaluating real-world experience, differences in race/ethnicity and among elderly patients with DLBCL appeared different from those seen in clinical trials, highlighting the need for consideration in these patient populations.

BTK Inhibitors, CAR T-Cell Therapy Drive Paradigm Changes in Follicular Lymphoma

Advancements in FL treatment, including BTK inhibitors and CAR T-cell therapies, offer new hope for relapsed or refractory cases.

Dr Moreno on the Pharmacodynamics of CLN-619 in Advanced Solid Tumors

Victor Moreno, MD, PhD, discusses insights into the pharmacodynamic activity of CLN-619 for patients with advanced solid tumors.

RP1 Plus Nivolumab Is Active, Safe in Advanced Melanoma After Progression on Anti–PD-1 Therapy

RP1 plus nivolumab generated responses in advanced melanoma that progressed on or after prior anti–PD-1 therapy.

IMA203 Produces Responses in Heavily Pretreated Advanced Melanoma, Other Solid Tumors

The investigational PRAME-targeted T-cell therapy IMA203 generated responses in melanoma and other solid tumors,

Invikafusp Alfa Demonstrates Single-Agent Activity in PD-(L)1–Resistant Solid Tumors

Phase 1 data showed the potential for invikafusp alfa as a precision cancer immunotherapeutic agent in solid tumors after exposure to PD-(L)1 therapy.

Temozolomide/Pembrolizumab Plus TTFields Leads to Tumor Control in Newly Diagnosed Glioblastoma

Patients with newly diagnosed glioblastoma had improved survival when treated with TTFields plus temozolomide and pembrolizumab.

E-602 Plus Cemiplimab Elicits Preliminary Antitumor Activity, Is Safe in PD-(L)1–Resistant Solid Tumors

E-602 plus cemiplimab elicited preliminary antitumor activity and had a tolerable safety profile in PD-(L)1–resistant solid tumors.

Fixed-Dose CAR T Cells Followed by Escalating UB-TT170 Increases Cytokine Levels in R/R Osteosarcoma

Administration of fixed-dose CAR T cells followed by escalating doses of UB-TT170 led to changes in cytokine levels in relapsed/refractory osteosarcoma.

THIO Plus Cemiplimab Displays Efficacy in Checkpoint Inhibitor–Resistant NSCLC

THIO plus cemiplimab displayed durable activity in patients with advanced checkpoint inhibitor–resistant NSCLC.

CD47 Levels Are Prognostic of Response to Magrolimab Plus Docetaxel in Metastatic NSCLC

Treatment with magrolimab plus docetaxel led to peripheral CD47 saturation in patients with advanced NSCLC, which correlated with improved outcomes.

Frontline Vibostolimab/Pembrolizumab Plus Chemo Meets Futility Threshold in ES-SCLC

Co-formulated vibostolimab and pembrolizumab plus chemotherapy failed to improve OS in the first line vs atezolizumab plus chemotherapy in ES-SCLC.

PD-L1, KIM-1 Expression Are Predictive of Outcomes With Adjuvant Nivolumab Alone, Plus Ipilimumab in ccRCC

The biomarker analysis of patients enrolled on part B of the CheckMate 914 trial explored the effects of PD-L1 and KIM-1 expression.

Preclinical Activity Support DLL3-TOPAbody in DLL3-Expressing SCLC and Other Tumors

Preclinical data suggest that DLL3-TOPAbody has antitumor activity and could provide a survival advantage in DLL3-expressing tumor cells, including SCLC.

DK210 (EGFR) Induces Immune Response Without Increased CRS or Regulatory T Cells in Solid Tumors

DK210 (EGFR) showed evidence of wild-type IL-2 signaling, CRS mitigation, and immune response signaling in patients with solid tumors.

Siglec-15 Represents Potential Therapeutic Target in NSCLC, Other Solid Tumors

Siglec-15 was expressed in tumor cells and tumor-associated macrophages in tissue samples from non–small cell lung cancer and other solid tumors.

Radiomic Biomarkers Predict Response in Lung and Liver Uveal Melanoma Metastases

Radiomic biomarkers can predict treatment response through assessments of tumor growth in patients with metastatic uveal melanoma treated with roginolisib.

BT7480 Shows Preliminary Activity in Nectin-4+, CD137+ Tumors

The Nectin-4/CD137 Bicycle–targeted immune cell agonist BT7480 had antitumor activity in patients with Nectin-4– and CD137-expressing tumors.

42nd Annual CFS Preview for Medical Oncologists: The Show and After Show

OncLive co-hosts Kristie L. Kahl and Andrew Svonavec talk to program co-chair Benjamin P. Levy, MD, to highlight what to expect in the latest oncology developments from the 42nd Annual Chemotherapy Foundation Symposium to be held in New York City.

Casdatifan Demonstrates Durable Activity in Metastatic Clear Cell Renal Cell Carcinoma

Casdatifan was well tolerated and had durable clinical activity in patients with metastatic clear cell renal cell carcinoma.

IDE397 Shows Early Antitumor Activity, Safety in MTAP-Deletion Urothelial Cancer and NSCLC

IDE397 is the first MAT2A inhibitor to show clinical activity and safety in patients with MTAP-deletion urothelial cancer and non–small cell lung cancer.